U.S., Aug. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07771621) titled 'PET Imaging With [18F]Fluselenamyl in People With Cardiac Amyloidosis' on July 30.
Brief Summary: This observational study will evaluate the imaging performance of the investigational positron emission tomography (PET) radiotracer[18F]Fluselenamyl (FSA) in individuals with cardiac amyloidosis. The study aims to determine whether [18F]Fluselenamyl PET imaging can detect and characterize amyloid deposits in the heart.
Participants will undergo PET imaging following administration of [18F]Fluselenamyl, along with clinical assessments and other study procedures as needed. Imaging results will be used to assess tracer uptake in the hear...